Dr. Yuan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Congress St Ste 200
Pasadena, CA 91105Phone+1 424-314-0190Fax+1 424-314-0193
Education & Training
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2007
- New York Downtown HospitalResidency, Internal Medicine, 2003 - 2006
- Xuzhou Medical CollegeClass of 1994
Certifications & Licensure
- CA State Medical License 2009 - 2027
- LA State Medical License 2021 - 2022
- NY State Medical License 2009 - 2012
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
- Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer Start of enrollment: 2014 Oct 01
Publications & Presentations
PubMed
- CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.Kim A Reiss, Mathew G Angelos, E Claire Dees, Yuan Yuan, Naoto T Ueno
Nature Medicine. 2025-02-07 - Association of Structural Maintenance of Chromosome-1A Phosphorylation with Progression of Breast Cancer.Sushma Yadav, Claudia M Kowolik, Daniel Schmolze, Yuan Yuan, Min Lin
Cells. 2025-01-17 - Demographic and clinical trends of young breast cancer patients from the national cancer database: disproportionate effect on minority populations.Cynthia Mark, Vivek Pujara, Marissa K Boyle, Yuan Yuan, Jin Sun Lee
Breast Cancer Research and Treatment. 2025-01-05
Journal Articles
- ERα-Mediated Cell Cycle Progression Is an Important Requisite for CDK4/6 Inhibitor Response in HR+ Breast CancerJoanne Mortimer, Laura Kruper, Raju Pillai, George Somlo, Yuan Yuan, Oncotarget
Press Mentions
- TNBC: Distinct Tumor Immune Microenvironments at Metastatic SitesJune 26th, 2024
Professional Memberships
- Member
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: